Affinivax

Affinivax is a biopharmaceutical company developing vaccines used to enhance the depth of protection against infectious diseases.

This novel and highly efficient vaccine conjugation technology – named MAPS for Multiple Antigen Presenting System – has the potential to deliver novel vaccines that offer broader disease coverage than existing vaccines, as well as protect against infectious diseases for which there are no effective immunization strategies today.

The company is rapidly advancing a lead program targeting Streptococcus pneumoniae (pneumococcus), a pathogen that is responsible for significant morbidity and mortality in children and adults worldwide. Affinivax was established based on the knowledge and insights of world-leading experts in the fields of infectious diseases and vaccines. The company is backed by an investment from the Bill & Melinda Gates Foundation and has an exclusive license from Boston Children’s Hospital for intellectual property related to the MAPS technology platform.

Affinivax headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Medical sector. The company focuses on Biotechnology and has secured $30.2B in funding across 80 round(s). With a team of 51-100 employees, Affinivax is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Affinivax, raised $2.5M. Discover more about their projects, partnerships, and impact on our platform.